An oral small molecule that blocks NNMT — preserving cellular NAD+ and SAM levels, with early data for fat loss, muscle regeneration, and metabolic health.
5-Amino-1-methylquinolinium, or 5-Amino-1MQ, is an oral small molecule inhibitor of NNMT (nicotinamide N-methyltransferase). NNMT methylates nicotinamide (vitamin B3) into a waste product, consuming both NAD+ precursors and SAM (methyl donors). Blocking NNMT preserves NAD+, SAM, and favorably shifts cellular metabolism.
Unlike most peptides on this site, 5-Amino-1MQ is a small molecule taken orally — no injections. It was developed academically and has not yet completed Phase 3 human trials, but the preclinical data are compelling for muscle regeneration, fat loss, and metabolic health.
Not FDA approved. Not WADA prohibited as of current list. Available as research chemical.
NNMT uses SAM (methyl donor) to convert nicotinamide into 1-MNA, which is excreted. Inhibiting NNMT preserves both NAD+ precursor pool and the SAM methyl-donor pool — critical for DNA methylation and hundreds of methylation reactions.
More nicotinamide available for the NAD+ salvage pathway means higher cellular NAD+ — a complementary mechanism to oral NMN or injectable NAD+.
NNMT is elevated in aging muscle and obesity-expanded adipose tissue. Inhibiting it in muscle enhances stem cell function (satellite cells) and in fat tissue increases metabolic rate and lipolysis.
| Benefit | Evidence |
|---|---|
| Fat loss | Mouse studies: ~7% body fat loss without caloric restriction |
| Muscle regeneration | Restored satellite cell function in aged mice; improved recovery from injury |
| Metabolic rate | Increased energy expenditure via enhanced fat oxidation |
| Insulin sensitivity | Preclinical improvements in glucose handling |
| NAD+ levels | Elevates cellular NAD+ via preserved nicotinamide |
Note: Human clinical data are limited. Most benefits are from preclinical models.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeStart at 50 mg/day for the first 1–2 weeks to assess tolerance before titrating up.
5-Amino-1MQ is taken orally as capsules — no reconstitution needed.
Pre-filled with a typical 5-Amino-1MQ setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Looking for 5-Amino-1MQ? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo. 5-Amino-1MQ has never been FDA approved and has not entered registered human clinical trials. It was developed at the University of Texas Medical Branch (Watowich lab) as an NNMT (nicotinamide N-methyltransferase) inhibitor. The molecule is sold only as a research chemical.
No — this is a frequent misconception. 5-Amino-1MQ is a small molecule (a quinolinium salt / methylated quinoline derivative), NOT a peptide. It is taken orally in capsule form. This distinguishes it from most of the compounds in the StackTrax library, which are injectable peptides.
Oral: community-practice 50–150 mg once daily, typically in the morning. Injectable: 1–5 mg subcutaneously once daily — much smaller mg quantities since SC bypasses any first-pass / GI losses. No human RCT-validated dose exists for either route; both ranges come from clinic and community convention based on allometric scaling of mouse studies.
Two routes are commercially available. Oral capsules (typically 50–100 mg) are the form used in all published preclinical research. Injectable preparations (e.g., 5 mg lyophilized vials, including NextGen Peptides) are sold by some research-grade vendors — pharmacology of the subcutaneous route has not been formally characterized in peer-reviewed studies, so dose-equivalence with oral is empirical rather than published. Choose based on availability and personal protocol.
It inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that consumes S-adenosyl-methionine (SAM) and nicotinamide (a NAD+ precursor) to produce 1-methylnicotinamide. By blocking NNMT, the molecule spares nicotinamide and SAM — indirectly supporting NAD+ levels and methylation-pool capacity in tissues that overexpress NNMT (adipose tissue, certain cancers). Mouse studies show fat-mass reduction without caloric restriction.
Not specifically named on the WADA Prohibited List as of 2025–2026. WADA reserves discretion under S0 (Non-Approved Substances) to sweep substances not currently listed elsewhere — 5-Amino-1MQ arguably falls under that umbrella. Competitive athletes should verify the current-year list before use.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.